ClinicalTrials.gg
RecruitingNCT06172322Updated Apr 23, 2024

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

A Phase 1 interventional study of NTQ1062 with Fulvestrant in HR Positive/HER-2 Negative Breast Cancer, sponsored by Nanjing Chia-tai Tianqing Pharmaceutical. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Nanjing Chia-tai Tianqing Pharmaceutical (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Planned enrollment
58th of 94
42 · median 71
Started
2023
with 3 others
Phase 1
6 of 95
1 open now
Primary completion
2025-04
later than 5 of 22 live
Registered
92nd of 95
by date

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 58th largest by planned enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 1, reaches primary completion later than 5 of the 22 other live ones, and was the 92nd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or metastatic HR positive/HER-2 negative breast cancer.

03

Conditions studied

  • HR Positive/HER-2 Negative Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged at least 18 years old at the time of .
  2. Premenopausal, perimenopausal, or women. Premenopausal and perimenopausal women must receive ovarian function suppression therapy during the study, and are willing to receive continuous treatment during the study.
  3. HR-positive or negative breast cancer as confirmed; or locally advanced disease that has recurred or progressed and for which, in the judgment of the investigator, curative surgery is not possible.
  4. score is 0-1.
  5. Predicted ≥3 months.
  6. Patients must have adequate organ function.
  7. Patients must be signed written informed consent prior to admission to the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients have received previous treatment with Fulvestrant or Akt inhibitors.
  2. Patients who have received chemotherapy, biological therapy, immunotherapy, radiotherapy and other anti-tumor therapy or participated in other therapeutic clinical studies (except observational clinical studies) from 4 weeks prior to the first dose.
  3. Treatment with systemic (prednisone > 10 mg/day or equivalent) or other agents for the treatment of non-neoplastic diseases within 14 days prior to the first dose.
  4. Patients received strong inhibitors and/or inducers of within 14 days or 5 drug half-lives prior to the first dose of study drug.
  5. Patients who have undergone major surgical procedures or significant traumatic injuries within 4 weeks prior to the first administration (excluding minor surgeries such as appendicitis and tumor ), or who require elective surgery during the trial period and are not suitable for clinical research.
  6. Patients who have a history of receiving attenuated or live vaccines within 4 weeks before the first administration, or who plan to receive such vaccines during the study period.
  7. Patients who have received prior hematopoietic stem cell transplantation or organ transplantation.
  8. The adverse reactions of previous anti-tumor therapy have not yet recovered to 5.0 level evaluation ≤ 1 level.
  9. Active or uncontrolled serious infection (≥ CTCAE Grade 2) or unexplained fever > 38.5 ℃ within 28 days prior to first dose.
  10. History of immunodeficiency, including positive antibody test.
  11. Patients with active hepatitis: those with positive B surface antigen (HBsAg) and more copies of HBV DNA than the positive value detected by the research center; Individuals who are positive for virus (HCV) antibodies and have tested positive for HCV RNA.
  12. Syphilis screening positive Patients.
  13. Previous medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
  14. History of serious cardiovascular and cerebrovascular diseases.
  15. nausea and vomiting, malabsorption syndrome, ulcerative colitis, symptomatic/inflammatory bowel disease, chronic diarrhea and intestinal obstruction and other serious gastrointestinal diseases, inability to take oral swallowing drugs, or the presence of conditions that seriously affect gastrointestinal absorption as judged by the investigator.
  16. Clinically uncontrolled third space effusion requiring repeated drainage or medical intervention (14 days prior to the first dose), which is not suitable based on the investigator's judgment.
  17. Known alcohol or drug dependence.
  18. Patients with mental disorders or poor compliance.
  19. Previous history of severe allergies, or allergies to any active or inactive ingredients such as NTQ1062, Fluvastatin, and LHRH agonists (if applicable, LHRH agonists are required during this study period)
  20. Pregnant or lactating women.
  21. Other conditions that the investigator considers inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    NTQ1062 with Fulvestrant

    NTQ1062 Tablets(200-500)+ Fulvestrant(500mg)

    Drug: NTQ1062 with Fulvestrant

Interventions

  • DrugNTQ1062 with Fulvestrant

    Drug pages: Akt Inhibitor NTQ1062 · Fulvestrant

    Drug: NTQ1062 tablet(s) ,PO,QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment). Drug: Fulvestrant Injection 500mg in a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    The MTD is defined as the highest dose reached for which the incidence of DLT occurs in less than 1/3 of the subjects.

    Time frame: First treatment cycle ( 28 days)

  2. Recommended phase 2 dose (RP2D)

    RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data.

    Time frame: Through study completion, an average of 1 year

  3. Adverse events

    Safety and tolerability of NTQ1062 in combination with Fluvastatin. Incidence of adverse events.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Pharmacokinetic parameters: Cmax

    Maximum Serum Concentration (Cmax) of NTQ1062 and NTQ1062-M.

    Time frame: At the end of Cycle 3 (each cycle is 28 days)

  2. Pharmacokinetic parameters: Tmax

    Time to Maximum Serum Concentration (Cmax) of NTQ1062 and NTQ1062-M.

    Time frame: At the end of Cycle 3 (each cycle is 28 days)

  3. Pharmacokinetic parameters: AUC

    The area under the concentration versus time curve of NTQ1062 and NTQ1062-M.

    Time frame: At the end of Cycle 3 (each cycle is 28 days)

  4. Pharmacokinetic parameters: T1/2

    The terminal half-life of NTQ1062 and NTQ1062-M.

    Time frame: At the end of Cycle 3 (each cycle is 28 days)

  5. Objective response rate (ORR)

    ORR is defined as participants with confirmed complete or partial response.

    Time frame: Through study completion, an average of 1 year

  6. Disease Control Rate (DCR)

    DCR was defined as the proportion of patients who had an overall response of complete response (CR), partial response (PR), or stable disease (SD).

    Time frame: Through study completion, an average of 1 year

  7. Duration of Response (DOR)

    DOR is defined as the time between date of first response and the first occurrence.

    Time frame: Through study completion, an average of 1 year

  8. Progression-free Survival (PFS)

    PFS will be defined as the time between the first dose of any study drug and the first occurrence of progression or death from any cause.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 201321, China
    Recruiting
    • jian Zhang · Contact
    • jian Zhang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2025, 16 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 16 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2023
First posted
Dec 15, 2023
StartActual
Dec 28, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Jul 2025
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06172322
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Dec 28, 2023
Primary completion
Apr 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Apr 23, 2024

Study contacts

Yu meng Zhou
Contact
zhouyumeng@njzdqt.com
86-025-85109999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Akt Inhibitor NTQ1062 · Fulvestrant

Start the discussion